Dendritic cells as therapeutic agents against cancer

Frontiers in Bioscience

Volumn 15, Issue 1, 2010, Pages 321-347

  Eksioglu, Erika A ^a   Eisen, Sarah ^b   Reddy, Vijay ^c  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c FLORIDA HOSPITAL   (United States)

Author keywords

Cancer vaccines; Dendritic cells; Review; Therapeutic adjuvants

Indexed keywords

CANCER VACCINE;

ADOPTIVE IMMUNOTHERAPY; ANIMAL; BIOLOGICAL MODEL; CLINICAL TRIAL; CYTOLOGY; DENDRITIC CELL; HUMAN; IMMUNOLOGY; MONONUCLEAR CELL; NEOPLASM; PATHOLOGY; REVIEW; TRANSPLANTATION; TREATMENT OUTCOME;

ANIMALS; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LEUKOCYTES, MONONUCLEAR; MODELS, BIOLOGICAL; NEOPLASMS; TREATMENT OUTCOME;

EID: 77951246916     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3623     Document Type: Article

References (168)

1. B. J. Gitlitz, A. S. Belldegrun, A. Zisman, D. H. Chao, A. J. Pantuck, A. Hinkel, P. Mulders, N. Moldawer, C. L. Tso and R. A. Figlin: A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma. J Immunother, 26 (5), 412-9 (2003). (Pubitemid 37128553)
2. S. F. Slovin: Dendritic cell vaccines-hopeful or hopeless? Cancer Invest, 21 (6), 969-70 (2003).
3. D. Ridgway: The first 1000 dendritic cell vaccinees. Cancer Invest, 21 (6), 873-86 (2003). (Pubitemid 38055985)
4. M. Cella, F. Sallusto and A. Lanzavecchia: Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol, 9 (1), 10-6 (1997). (Pubitemid 27095893)
5. J. Banchereau and R. M. Steinman: Dendritic cells and the control of immunity. Nature, 392 (6673), 245-52 (1998). (Pubitemid 28155090)
6. C. Ardavin, G. Martinez del Hoyo, P. Martin, F. Anjuere, C. F. Arias, A. R. Marin, S. Ruiz, V. Parrillas and H. Hernandez: Origin and differentiation of dendritic cells. Trends Immunol, 22 (12), 691-700 (2001). (Pubitemid 34008606)
7. F. O. Nestle, J. Banchereau and D. Hart: Dendritic cells: On the move from bench to bedside. Nat Med, 7 (7), 761-5 (2001). (Pubitemid 32691622)
8. H. S. Pandha, R. J. John, J. Hutchinson, N. James, M. Whelan, C. Corbishley and A. G. Dalgleish: Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study. BJU Int, 94 (3), 412-8 (2004). (Pubitemid 39120190)
9. R. M. Steinman: Dendritic cells and the control of immunity: enhancing the efficiency of antigen presentation. Mt Sinai J Med, 68 (3), 160-6 (2001). (Pubitemid 33606184)
10. C. M. Hilkens, P. Kalinski, M. de Boer and M. L. Kapsenberg: Human dendritic cells require exogenous interleukin-12-inducing factors to direct the development of naive T-helper cells toward the Th1 phenotype. Blood, 90 (5), 1920-6 (1997). (Pubitemid 27377302)
11. L. Fong and E. G. Engleman: Dendritic cells in cancer immunotherapy. Annu Rev Immunol, 18, 245-73 (2000). (Pubitemid 30365381)
12. C. Ardavin: Dendritic cell heterogeneity: developmental plasticity and functional diversity. Semin Immunol, 17 (4), 251-2 (2005). (Pubitemid 40981930)
13. K. Shortman and Y. J. Liu: Mouse and human dendritic cell subtypes. Nat Rev Immunol, 2 (3), 151-61 (2002). (Pubitemid 37336516)
14. S. A. Rosenberg, J. C. Yang, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. Topalian, N. P. Restifo, M. E. Dudley, S. L. Schwarz, P. J. Spiess, J. R. Wunderlich, M. R. Parkhurst, Y. Kawakami, C. A. Seipp, J. H. Einhorn and D. E. White: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med, 4 (3), 321-7 (1998). (Pubitemid 28144091)
15. R. E. Toes, F. Ossendorp, R. Offringa and C. J. Melief: CD4 T cells and their role in antitumor immune responses. J Exp Med, 189 (5), 753-6 (1999). (Pubitemid 29189679)
16. P. A. Cohen, L. Peng, G. E. Plautz, J. A. Kim, D. E. Weng and S. Shu: CD4+ T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection. Crit Rev Immunol, 20 (1), 17-56 (2000). (Pubitemid 30191901)
17. F. Ossendorp, E. Mengede, M. Camps, R. Filius and C. J. Melief: Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med, 187 (5), 693-702 (1998). (Pubitemid 28115185)
18. R. F. Wang: The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity. Trends Immunol, 22 (5), 269-76 (2001).
19. J. Babatz, C. Rollig, U. Oelschlagel, S. Zhao, G. Ehninger, M. Schmitz and M. Bornhauser: Large-scale immunomagnetic selection of CD14+ monocytes to generate dendritic cells for cancer immunotherapy: a phase I study. J Hematother Stem Cell Res, 12 (5), 515-23 (2003). (Pubitemid 37305564)
20. J. Baggers, G. Ratzinger and J. W. Young: Dendritic cells as immunologic adjuvants for the treatment of cancer. J Clin Oncol, 18 (23), 3879-82 (2000).
21. S. Vandenabeele, H. Hochrein, N. Mavaddat, K. Winkel and K. Shortman: Human thymus contains 2 distinct dendritic cell populations. Blood, 97 (6), 1733-41 (2001). (Pubitemid 32217241)
22. N. Bendriss-Vermare, C. Barthelemy, I. Durand, C. Bruand, C. Dezutter-Dambuyant, N. Moulian, S. Berrih- Aknin, C. Caux, G. Trinchieri and F. Briere: Human thymus contains IFN-alpha-producing CD11c (-), myeloid CD11c (+), and mature interdigitating dendritic cells. J Clin Invest, 107 (7), 835-44 (2001). (Pubitemid 32274036)
23. K. Liu, G. D. Victora, T. A. Schwickert, P. Guermonprez, M. M. Meredith, K. Yao, F. F. Chu, G. J. Randolph, A. Y. Rudensky and M. Nussenzweig: In vivo analysis of dendritic cell development and homeostasis. Science, 324 (5925), 392-7 (2009).
24. B. Pulendran, J. Banchereau, E. Maraskovsky and C. Maliszewski: Modulating the immune response with dendritic cells and their growth factors. Trends Immunol, 22 (1), 41-7 (2001). (Pubitemid 32675280)
25. C. Ardavin, S. Amigorena and C. Reis e Sousa: Dendritic cells: immunobiology and cancer immunotherapy. Immunity, 20 (1), 17-23 (2004). (Pubitemid 38134290)
26. M. C. Rissoan, V. Soumelis, N. Kadowaki, G. Grouard, F. Briere, R. de Waal Malefyt and Y. J. Liu: Reciprocal control of T helper cell and dendritic cell differentiation. Science, 283 (5405), 1183-6 (1999).
27. K. Bottomly: T cells and dendritic cells get intimate. Science, 283 (5405), 1124-5 (1999).
28. G. Dranoff: Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer, 4 (1), 11-22 (2004). (Pubitemid 38111131)
29. D. S. Whittaker, K. S. Bahjat, L. L. Moldawer and M. J. Clare-Salzler: Autoregulation of human monocyte-derived dendritic cell maturation and IL-12 production by cyclooxygenase-2-mediated prostanoid production. J Immunol, 165 (8), 4298-304 (2000).
30. J. Rengarajan, S. J. Szabo and L. H. Glimcher: Transcriptional regulation of Th1/Th2 polarization. Immunol Today, 21 (10), 479-83 (2000).
31. R. M. Syme, P. Duggan, D. Stewart and S. Gluck: Generation of dendritic cells ex vivo: differences in steady state versus mobilized blood from patients with breast cancer, with lymphoma, and from normal donors. J Hematother Stem Cell Res, 10 (5), 621-30 (2001). (Pubitemid 32988612)
32. M. P. Buzzeo, J. Yang, G. Casella and V. Reddy: Hematopoietic stem cell mobilization with G-CSF induces innate inflammation yet suppresses adaptive immune gene expression as revealed by microarray analysis. Exp Hematol, 35 (9), 1456-65 (2007). (Pubitemid 47302592)
33. S. Balan, V. P. Kale and L. S. Limaye: A simple twostep culture system for the large-scale generation of mature and functional dendritic cells from umbilical cord blood CD34+ cells. Transfusion (2009).
34. G. Ferlazzo, A. Wesa, W. Z. Wei and A. Galy: Dendritic cells generated either from CD34+ progenitor cells or from monocytes differ in their ability to activate antigen-specific CD8+ T cells. J Immunol, 163 (7), 3597- 604 (1999). (Pubitemid 29450879)
35. G. Meierhoff, S. W. Krause and R. Andreesen: Comparative analysis of dendritic cells derived from blood monocytes or CD34+ hematopoietic progenitor cells. Immunobiology, 198 (5), 501-13 (1998). (Pubitemid 28143087)
36. R. Mortarini, A. Anichini, M. Di Nicola, S. Siena, M. Bregni, F. Belli, A. Molla, A. M. Gianni and G. Parmiani: Autologous dendritic cells derived from CD34+ progenitors and from monocytes are not functionally equivalent antigen-presenting cells in the induction of melan-A/Mart-1 (27-35)-specific CTLs from peripheral blood lymphocytes of melanoma patients with low frequency of CTL precursors. Cancer Res, 57 (24), 5534- 41 (1997). (Pubitemid 28006761)
37. Y. Matsunaga, D. Fukuma, S. Hirata, S. Fukushima, M. Haruta, T. Ikeda, I. Negishi, Y. Nishimura and S. Senju: Activation of antigen-specific cytotoxic T lymphocytes by beta 2-microglobulin or TAP1 gene disruption and the introduction of recipient-matched MHC class I gene in allogeneic embryonic stem cell-derived dendritic cells. J Immunol, 181 (9), 6635-43 (2008).
38. S. Fukushima, S. Hirata, Y. Motomura, D. Fukuma, Y. Matsunaga, Y. Ikuta, T. Ikeda, T. Kageshita, H. Ihn, Y. Nishimura and S. Senju: Multiple antigen-targeted immunotherapy with alpha-galactosylceramide-loaded and genetically engineered dendritic cells derived from embryonic stem cells. J Immunother, 32 (3), 219-31 (2009).
39. S. Senju, H. Suemori, H. Zembutsu, Y. Uemura, S. Hirata, D. Fukuma, H. Matsuyoshi, M. Shimomura, M. Haruta, S. Fukushima, Y. Matsunaga, T. Katagiri, Y. Nakamura, M. Furuya, N. Nakatsuji and Y. Nishimura: Genetically manipulated human embryonic stem cellderived dendritic cells with immune regulatory function. Stem Cells, 25 (11), 2720-9 (2007). (Pubitemid 350127856)
40. J. M. Timmerman and R. Levy: Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med, 50, 507-29 (1999). (Pubitemid 29117080)
41. J. J. Everly and S. Lonial: Immunomodulatory effects of human recombinant granulocyte-macrophage colonystimulating factor (rhuGM-CSF): evidence of antitumour activity. Expert Opin Biol Ther, 5 (3), 293-311 (2005). (Pubitemid 40516741)
42. J. Banchereau and A. K. Palucka: Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol, 5 (4), 296-306 (2005). (Pubitemid 40516155)
43. G. Dranoff, E. Jaffee, A. Lazenby, P. Golumbek, H. Levitsky, K. Brose, V. Jackson, H. Hamada, D. Pardoll and R. C. Mulligan: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A, 90 (8), 3539-43 (1993). (Pubitemid 23111402)
44. G. Dranoff and R. C. Mulligan: Activities of granulocyte-macrophage colony-stimulating factor revealed by gene transfer and gene knockout studies. Stem Cells, 12 Suppl 1, 173-82; discussion 182-4 (1994).
45. G. Dranoff: GM-CSF-based cancer vaccines. Immunol Rev, 188, 147-54 (2002). (Pubitemid 35398872)
46. R. Hurtado, M. Candelaria, F. Vargas, A. Majluf, F. Bolanos and J. R. Labardini: rHuGM-CSF after high-dose chemotherapy in post-remission acute leukemia. Stem Cells, 13 (2), 112-22 (1995).
47. J. C. Gluckman, B. Canque, F. Chapuis and M. Rosenzwajg: In vitro generation of human dendritic cells and cell therapy. Cytokines Cell Mol Ther, 3 (3), 187-96 (1997). (Pubitemid 27448282)
48. G. M. Zou and Y. K. Tam: Cytokines in the generation and maturation of dendritic cells: recent advances. Eur Cytokine Netw, 13 (2), 186-99 (2002). (Pubitemid 34747919)
49. S. M. Kiertscher, B. J. Gitlitz, R. A. Figlin and M. D. Roth: Granulocyte/macrophage-colony stimulating factor and interleukin-4 expand and activate type-1 dendritic cells (DC1) when administered in vivo to cancer patients. Int J Cancer, 107 (2), 256-61 (2003). (Pubitemid 37152906)
50. A. Soruri and J. Zwirner: Dendritic cells: limited potential in immunotherapy. Int J Biochem Cell Biol, 37 (2), 241-5 (2005). (Pubitemid 39330183)
51. E. A. Eksioglu, S. S. Mahmood, M. Chang and V. Reddy: GM-CSF promotes differentiation of human dendritic cells and T lymphocytes toward a predominantly type 1 proinflammatory response. Exp Hematol, 35 (8), 1163-71 (2007). (Pubitemid 47088777)
52. I. D. Davis, Q. Chen, L. Morris, J. Quirk, M. Stanley, M. L. Tavarnesi, P. Parente, T. Cavicchiolo, W. Hopkins, H. Jackson, N. Dimopoulos, T. Y. Tai, D. MacGregor, J. Browning, S. Svobodova, D. Caron, E. Maraskovsky, L. J. Old, W. Chen and J. Cebon: Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients. J Immunother, 29 (5), 499- 511 (2006). (Pubitemid 44395275)
53. L. Fong, D. Brockstedt, C. Benike, J. K. Breen, G. Strang, C. L. Ruegg and E. G. Engleman: Dendritic cellbased xenoantigen vaccination for prostate cancer immunotherapy. J Immunol, 167 (12), 7150-6 (2001). (Pubitemid 33144213)
54. Y. Ueda, T. Itoh, N. Fuji, S. Harada, H. Fujiki, K. Shimizu, A. Shiozaki, A. Iwamoto, T. Shimizu, O. Mazda, T. Kimura, Y. Sonoda, M. Taniwaki and H. Yamagishi: Successful induction of clinically competent dendritic cells from granulocyte colony-stimulating factor-mobilized monocytes for cancer vaccine therapy. Cancer Immunol Immunother, 56 (3), 381-9 (2007). (Pubitemid 46035906)
55. L. Fong, D. Brockstedt, C. Benike, L. Wu and E. G. Engleman: Dendritic cells injected via different routes induce immunity in cancer patients. J Immunol, 166 (6), 4254-9 (2001). (Pubitemid 32224961)
56. A. Escobar, M. Lopez, A. Serrano, M. Ramirez, C. Perez, A. Aguirre, R. Gonzalez, J. Alfaro, M. Larrondo, M. Fodor, C. Ferrada and F. Salazar-Onfray: Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients. Clin Exp Immunol, 142 (3), 555-68 (2005). (Pubitemid 41719853)
57. A. Curti, A. Isidori, E. Ferri, C. Terragna, P. Neyroz, C. Cellini, M. Ratta, M. Baccarani and R. M. Lemoli: Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy. Leuk Lymphoma, 45 (7), 1419-28 (2004). (Pubitemid 38701920)
58. H. T. Maecker, J. Moon, S. Bhatia, S. A. Ghanekar, V. C. Maino, J. K. Payne, K. Kuus-Reichel, J. C. Chang, A. Summers, T. M. Clay, M. A. Morse, H. K. Lyerly, C. DeLaRosa, D. P. Ankerst and M. L. Disis: Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT. BMC Immunol, 6, 17 (2005).
59. V. Quillien, A. Moisan, A. Carsin, T. Lesimple, C. Lefeuvre, H. Adamski, N. Bertho, A. Devillers, C. Leberre and L. Toujas: Biodistribution of radiolabelled human dendritic cells injected by various routes. Eur J Nucl Med Mol Imaging, 32 (7), 731-41 (2005). (Pubitemid 41125414)
60. S. Adams, D. O'Neill and N. Bhardwaj: Maturation matters: importance of maturation for antitumor immunity of dendritic cell vaccines. J Clin Oncol, 22 (18), 3834-5; author reply 3835 (2004).
61. A. Stift, M. Sachet, R. Yagubian, C. Bittermann, P. Dubsky, C. Brostjan, R. Pfragner, B. Niederle, R. Jakesz, M. Gnant and J. Friedl: Dendritic cell vaccination in medullary thyroid carcinoma. Clin Cancer Res, 10 (9), 2944-53 (2004). (Pubitemid 38619669)
62. A. Ribas, J. A. Glaspy, Y. Lee, V. B. Dissette, E. Seja, H. T. Vu, N. S. Tchekmedyian, D. Oseguera, B. Comin-Anduix, J. A. Wargo, S. N. Amarnani, W. H. McBride, J. S. Economou and L. H. Butterfield: Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy. J Immunother, 27 (5), 354-67 (2004). (Pubitemid 39121924)
63. M. Trakatelli, M. Toungouz, D. Blocklet, Y. Dodoo, L. Gordower, M. Laporte, P. Vereecken, F. Sales, L. Mortier, N. Mazouz, M. Lambermont, S. Goldman, P. Coulie, M. Goldman and T. Velu: A new dendritic cell vaccine generated with interleukin-3 and interferon-beta induces CD8+ T cell responses against NA17-A2 tumor peptide in melanoma patients. Cancer Immunol Immunother, 55 (4), 469-74 (2006). (Pubitemid 43076899)
64. B. Kavanagh, A. Ko, A. Venook, K. Margolin, H. Zeh, M. Lotze, B. Schillinger, W. Liu, Y. Lu, P. Mitsky, M. Schilling, N. Bercovici, M. Loudovaris, R. Guillermo, S. M. Lee, J. Bender, B. Mills and L. Fong: Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. J Immunother, 30 (7), 762-72 (2007). (Pubitemid 47480759)
65. P. Hellman and H. Eriksson: Early activation markers of human peripheral dendritic cells. Hum Immunol, 68 (5), 324-33 (2007). (Pubitemid 46616974)
66. S. Ebner, G. Ratzinger, B. Krosbacher, M. Schmuth, A. Weiss, D. Reider, R. A. Kroczek, M. Herold, C. Heufler, P. Fritsch and N. Romani: Production of IL-12 by human monocyte-derived dendritic cells is optimal when the stimulus is given at the onset of maturation, and is further enhanced by IL-4. J Immunol, 166 (1), 633-41 (2001). (Pubitemid 32038487)
67. S. E. Jacobsen, C. Okkenhaug, J. Myklebust, O. P. Veiby and S. D. Lyman: The FLT3 ligand potently and directly stimulates the growth and expansion of primitive murine bone marrow progenitor cells in vitro: synergistic interactions with interleukin (IL) 11, IL-12, and other hematopoietic growth factors. J Exp Med, 181 (4), 1357-63 (1995).
68. M. Shackleton, I. D. Davis, W. Hopkins, H. Jackson, N. Dimopoulos, T. Tai, Q. Chen, P. Parente, M. Jefford, K. A. Masterman, D. Caron, W. Chen, E. Maraskovsky and J. Cebon: The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immun, 4, 9 (2004).
69. E. A. Hirschowitz, T. Foody, R. Kryscio, L. Dickson, J. Sturgill and J. Yannelli: Autologous dendritic cell vaccines for non-small-cell lung cancer. J Clin Oncol, 22 (14), 2808- 15 (2004). (Pubitemid 41079898)
70. C. Thery, L. Zitvogel and S. Amigorena: Exosomes: composition, biogenesis and function. Nat Rev Immunol, 2 (8), 569-79 (2002). (Pubitemid 37328732)
71. L. Zitvogel, A. Regnault, A. Lozier, J. Wolfers, C. Flament, D. Tenza, P. Ricciardi-Castagnoli, G. Raposo and S. Amigorena: Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med, 4 (5), 594-600 (1998). (Pubitemid 28237359)
72. V. Reddy: Granulocyte colony-stimulating factor mobilization alters dendritic cell cytokine production and initiates T helper 2 polarization prior to host alloantigen presentation. Blood, 96 (7), 2635 (2000).
73. V. Reddy, J. A. Iturraspe, A. C. Tzolas, H. U. Meier- Kriesche, J. Schold and J. R. Wingard: Low dendritic cell count after allogeneic hematopoietic stem cell transplantation predicts relapse, death, and acute graftversus- host disease. Blood, 103 (11), 4330-5 (2004). (Pubitemid 38685381)
74. V. Reddy, A. G. Winer, E. Eksioglu, H. U. Meier- Kriesche, J. D. Schold and J. R. Wingard: Interleukin 12 is associated with reduced relapse without increased incidence of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant, 11 (12), 1014-21 (2005). (Pubitemid 41754720)
75. Y. G. Yang, B. Dey, J. J. Sergio and M. Sykes: Interleukin-12 prevents severe acute graft-versus-host disease (GVHD) and GVHD-associated immune dysfunction in a fully major histocompatibility complex haplotype-mismatched murine bone marrow transplantation model. Transplantation, 64 (9), 1343-52 (1997). (Pubitemid 27495970)
76. J. Nemunaitis: Cytokine-mobilized peripheral blood progenitor cells. Semin Oncol, 23 (2 Suppl 4), 9-14 (1996). (Pubitemid 26127204)
77. K. Welte, J. Gabrilove, M. H. Bronchud, E. Platzer and G. Morstyn: Filgrastim (r-metHuG-CSF): the first 10 years. Blood, 88 (6), 1907-29 (1996). (Pubitemid 26307891)
78. M. Arpinati, C. L. Green, S. Heimfeld, J. E. Heuser and C. Anasetti: Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood, 95 (8), 2484-90 (2000). (Pubitemid 30210524)
79. E. M. Sloand, S. Kim, J. P. Maciejewski, F. Van Rhee, A. Chaudhuri, J. Barrett and N. S. Young: Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo. Blood, 95 (7), 2269-74 (2000). (Pubitemid 30167724)
80. V. Pullarkat, P. P. Lee, R. Scotland, V. Rubio, S. Groshen, C. Gee, R. Lau, J. Snively, S. Sian, S. L. Woulfe, R. A. Wolfe and J. S. Weber: A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanoma. Clin Cancer Res, 9 (4), 1301-12 (2003). (Pubitemid 36418380)
81. I. Volpi, K. Perruccio, A. Tosti, M. Capanni, L. Ruggeri, S. Posati, F. Aversa, A. Tabilio, L. Romani, M. F. Martelli and A. Velardi: Postgrafting administration of granulocyte colony-stimulating factor impairs functional immune recovery in recipients of human leukocyte antigen haplotype-mismatched hematopoietic transplants. Blood, 97 (8), 2514-21 (2001). (Pubitemid 32291500)
82. G. R. Hill and J. L. Ferrara: The primacy of the gastrointestinal tract as a target organ of acute graft-versushost disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood, 95 (9), 2754-9 (2000). (Pubitemid 30235880)
83. M. L. Nasi, P. Lieberman, K. J. Busam, V. Prieto, K. S. Panageas, J. J. Lewis, A. N. Houghton and P. B. Chapman: Intradermal injection of granulocyte-macrophage colonystimulating factor (GM-CSF) in patients with metastatic melanoma recruits dendritic cells. Cytokines Cell Mol Ther, 5 (3), 139-44 (1999). (Pubitemid 29481350)
84. S. Lonial, M. Hicks, H. Rosenthal, A. Langston, I. Redei, C. Torre, M. Duenzl, B. Feinstein, J. Cherry and E. K. Waller: A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products. Biol Blood Marrow Transplant, 10 (12), 848-57 (2004).
85. J. W. Simons and N. Sacks: Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer. Urol Oncol, 24 (5), 419-24 (2006). (Pubitemid 44311548)
86. K. M. Hege, K. Jooss and D. Pardoll: GM-CSF genemodifed cancer cell immunotherapies: of mice and men. Int Rev Immunol, 25 (5-6), 321-52 (2006). (Pubitemid 44972270)
87. E. K. Waller and M. S. Ernstoff: Modulation of antitumor immune responses by hematopoietic cytokines. Cancer, 97 (7), 1797-809 (2003). (Pubitemid 36350724)
88. A. Fattorossi, A. Battaglia, L. Pierelli, P. Malinconico, L. Andreocci, A. Perillo, G. Ferrandina, O. Martelli, A. Rughetti, M. Nuti, E. Cortesi and G. Scambia: Effects of granulocyte-colony-stimulating factor and granulocyte/macrophage-colony-stimulating factor administration on T cell proliferation and phagocyte cell surface molecules during hematopoietic reconstitution after autologous peripheral blood progenitor cell transplantation. Cancer Immunol Immunother, 49 (12), 641-8 (2001). (Pubitemid 32656625)
89. M. A. Lowes, G. A. Bishop, K. Crotty, R. S. Barnetson and G. M. Halliday: T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanomas. J Invest Dermatol, 108 (6), 914-9 (1997). (Pubitemid 27272409)
90. E. A. Mittendorf, C. E. Storrer, R. J. Foley, K. Harris, Y. Jama, C. D. Shriver, S. Ponniah and G. E. Peoples: Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial. Cancer, 106 (11), 2309-17 (2006). (Pubitemid 43787653)
91. R. O. Dillman, M. Wiemann, S. K. Nayak, C. DeLeon, K. Hood and C. DePriest: Interferon-gamma or granulocyte-macrophage colony-stimulating factor administered as adjuvants with a vaccine of irradiated autologous tumor cells from short-term cell line cultures: a randomized phase 2 trial of the cancer biotherapy research group. J Immunother, 26 (4), 367-73 (2003). (Pubitemid 36858721)
92. R. Dillman, S. Selvan, P. Schiltz, C. Peterson, K. Allen, C. Depriest, E. McClay, N. Barth, P. Sheehy, C. de Leon and L. Beutel: Phase I/II trial of melanoma patient-specific vaccine of proliferating autologous tumor cells, dendritic cells, and GM-CSF: planned interim analysis. Cancer Biother Radiopharm, 19 (5), 658-65 (2004). (Pubitemid 39546306)
93. M. Lopez, A. Escobar, J. Alfaro, M. Fodor, M. Larrondo, C. Ferrada and F. Salazar-Onfray: (Advances in cellular immunotherapy for malignant melanoma). Rev Med Chil, 132 (9), 1115-26 (2004).
94. P. A. Stumbles, J. A. Thomas, C. L. Pimm, P. T. Lee, T. J. Venaille, S. Proksch and P. G. Holt: Resting respiratory tract dendritic cells preferentially stimulate T helper cell type 2 (Th2) responses and require obligatory cytokine signals for induction of Th1 immunity. J Exp Med, 188 (11), 2019-31 (1998). (Pubitemid 28562519)
95. I. Bleumer, D. M. Tiemessen, J. C. Oosterwijk-Wakka, M. C. Voller, K. De Weijer, P. F. Mulders and E. Oosterwijk: Preliminary analysis of patients with progressive renal cell carcinoma vaccinated with CA9- peptide-pulsed mature dendritic cells. J Immunother, 30 (1), 116-22 (2007). (Pubitemid 46052210)
96. S. Perambakam, S. Hallmeyer, S. Reddy, N. Mahmud, L. Bressler, P. DeChristopher, D. Mahmud, R. Nunez, J. A. Sosman and D. J. Peace: Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146-154 peptide. Cancer Immunol Immunother, 55 (9), 1033-42 (2006). (Pubitemid 43800718)
97. J. Westermann, J. Kopp, A. van Lessen, A. C. Hecker, G. Baskaynak, P. le Coutre, K. Dohner, H. Dohner, B. Dorken and A. Pezzutto: Vaccination with autologous nonirradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia. Br J Haematol, 137 (4), 297-306 (2007). (Pubitemid 46650246)
98. M. L. Disis, K. Rinn, K. L. Knutson, D. Davis, D. Caron, C. dela Rosa and K. Schiffman: Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptidebased vaccines in patients with HER-2/neu-overexpressing cancers. Blood, 99 (8), 2845-50 (2002). (Pubitemid 34525373)
99. A. Berntsen, P. F. Geertsen and I. M. Svane: Therapeutic dendritic cell vaccination of patients with renal cell carcinoma. Eur Urol, 50 (1), 34-43 (2006). (Pubitemid 43850125)
100. K. A. Chianese-Bullock, E. M. Woodson, H. Tao, S. A. Boerner, M. Smolkin, W. W. Grosh, P. Y. Neese, P. Merrill, G. R. Petroni and C. L. Slingluff Jr.: Autoimmune toxicities associated with the administration of antitumor vaccines and low-dose interleukin-2. J Immunother, 28 (4), 412-9 (2005). (Pubitemid 40962336)
101. I. M. Svane, A. E. Pedersen, J. S. Johansen, H. E. Johnsen, D. Nielsen, C. Kamby, S. Ottesen, E. Balslev, E. Gaarsdal, K. Nikolajsen and M. H. Claesson: Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers. Cancer Immunol Immunother, 56 (9), 1485-99 (2007). (Pubitemid 47024713)
102. B. Hildenbrand, B. Sauer, O. Kalis, C. Stoll, M. A. Freudenberg, G. Niedermann, J. M. Giesler, E. Juttner, J. H. Peters, B. Haring, R. Leo, C. Unger and M. Azemar: Immunotherapy of patients with hormone-refractory prostate carcinoma pre-treated with interferon-gamma and vaccinated with autologous PSA-peptide loaded dendritic cells-a pilot study. Prostate, 67 (5), 500-8 (2007). (Pubitemid 46536943)
103. S. J. Antonia, N. Mirza, I. Fricke, A. Chiappori, P. Thompson, N. Williams, G. Bepler, G. Simon, W. Janssen, J. H. Lee, K. Menander, S. Chada and D. I. Gabrilovich: Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res, 12 (3 Pt 1), 878-87 (2006). (Pubitemid 43259871)
104. L. Holtl, R. Ramoner, C. Zelle-Rieser, H. Gander, T. Putz, C. Papesh, W. Nussbaumer, C. Falkensammer, G. Bartsch and M. Thurnher: Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide. Cancer Immunol Immunother, 54 (7), 663-70 (2005). (Pubitemid 40884162)
105. B. J. Czerniecki, G. K. Koski, U. Koldovsky, S. Xu, P. A. Cohen, R. Mick, H. Nisenbaum, T. Pasha, M. Xu, K. R. Fox, S. Weinstein, S. G. Orel, R. Vonderheide, G. Coukos, A. DeMichele, L. Araujo, F. R. Spitz, M. Rosen, B. L. Levine, C. June and P. J. Zhang: Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res, 67 (4), 1842-52 (2007). (Pubitemid 46383411)
106. J. Wierecky, M. R. Muller, S. Wirths, E. Halder-Oehler, D. Dorfel, S. M. Schmidt, M. Hantschel, W. Brugger, S. Schroder, M. S. Horger, L. Kanz and P. Brossart: Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res, 66 (11), 5910- 8 (2006). (Pubitemid 43927146)
107. N. Sadanaga, H. Nagashima, K. Mashino, K. Tahara, H. Yamaguchi, M. Ohta, T. Fujie, F. Tanaka, H. Inoue, K. Takesako, T. Akiyoshi and M. Mori: Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin Cancer Res, 7 (8), 2277-84 (2001). (Pubitemid 32751625)
108. K. H. Chi, S. J. Liu, C. P. Li, H. P. Kuo, Y. S. Wang, Y. Chao and S. L. Hsieh: Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma. J Immunother, 28 (2), 129-35 (2005). (Pubitemid 40328199)
109. D. E. Avigan, B. Vasir, D. J. George, W. K. Oh, M. B. Atkins, D. F. McDermott, P. W. Kantoff, R. A. Figlin, M. J. Vasconcelles, Y. Xu, D. Kufe and R. M. Bukowski: Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Immunother, 30 (7), 749-61 (2007). (Pubitemid 47480758)
110. J. A. Kyte, G. Kvalheim, K. Lislerud, P. thor Straten, S. Dueland, S. Aamdal and G. Gaudernack: T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells. Cancer Immunol Immunother, 56 (5), 659-75 (2007). (Pubitemid 46348735)
111. R. H. Vonderheide, W. C. Hahn, J. L. Schultze and L. M. Nadler: The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity, 10 (6), 673-9 (1999). (Pubitemid 29302920)
112. W. N. Haining, J. Davies, H. Kanzler, L. Drury, T. Brenn, J. Evans, J. Angelosanto, S. Rivoli, K. Russell, S. George, P. Sims, D. Neuberg, X. Li, J. Kutok, J. Morgan, P. Wen, G. Demetri, R. L. Coffman and L. M. Nadler: CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans. Clin Cancer Res, 14 (17), 5626-34 (2008).
113. E. A. Hirschowitz, T. Foody, G. E. Hidalgo and J. R. Yannelli: Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells. Lung Cancer, 57 (3), 365-72 (2007). (Pubitemid 47285427)
114. Y. Wei, R. P. Sticca, L. M. Holmes, K. E. Burgin, J. Li, J. Williamson, L. Evans, S. J. Smith, J. J. Stephenson and T. E. Wagner: Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses. Int J Oncol, 28 (3), 585-93 (2006).
115. H. Roddie, M. Klammer, C. Thomas, R. Thomson, A. Atkinson, A. Sproul, M. Waterfall, K. Samuel, J. Yin, P. Johnson and M. Turner: Phase I/II study of vaccination with dendritic-like leukaemia cells for the immunotherapy of acute myeloid leukaemia. Br J Haematol, 133 (2), 152-7 (2006).
116. J. Wierecky, M. Mueller and P. Brossart: Dendritic cell-based cancer immunotherapy targeting MUC-1. Cancer Immunol Immunother, 55 (1), 63-7 (2006). (Pubitemid 41783295)
117. L. Holtl, C. Rieser, C. Papesh, R. Ramoner, G. Bartsch and M. Thurnher: CD83+ blood dendritic cells as a vaccine for immunotherapy of metastatic renal-cell cancer. Lancet, 352 (9137), 1358 (1998). (Pubitemid 28510923)
118. C. E. Thomas, A. Ehrhardt and M. A. Kay: Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet, 4 (5), 346-58 (2003). (Pubitemid 36538359)
119. B. Gansbacher, K. Zier, K. Cronin, P. A. Hantzopoulos, B. Bouchard, A. Houghton, E. Gilboa and D. Golde: Retroviral gene transfer induced constitutive expression of interleukin-2 or interferon-gamma in irradiated human melanoma cells. Blood, 80 (11), 2817-25 (1992).
120. H. Mok, D. J. Palmer, P. Ng and M. A. Barry: Evaluation of polyethylene glycol modification of firstgeneration and helper-dependent adenoviral vectors to reduce innate immune responses. Mol Ther, 11 (1), 66-79 (2005) doi:S1525-0016 (04)01463-7 (pii)10.1016/j.ymthe.2004.09.015. (Pubitemid 40012000)
121. D. A. Muruve: The innate immune response to adenovirus vectors. Hum Gene Ther, 15 (12), 1157-66 (2004). (Pubitemid 40052429)
122. T. Osada, T. Clay, A. Hobeika, H. K. Lyerly and M. A. Morse: NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity. Cancer Immunol Immunother, 55 (9), 1122-31 (2006). (Pubitemid 43800727)
123. M. A. Morse, T. M. Clay, A. C. Hobeika, T. Osada, S. Khan, S. Chui, D. Niedzwiecki, D. Panicali, J. Schlom and H. K. Lyerly: Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin Cancer Res, 11 (8), 3017-24 (2005). (Pubitemid 40525207)
124. R. G. Meyer, C. M. Britten, U. Siepmann, B. Petzold, T. A. Sagban, H. A. Lehr, B. Weigle, M. Schmitz, L. Mateo, B. Schmidt, H. Bernhard, T. Jakob, R.
125. M. Di Nicola, C. Carlo-Stella, R. Mortarini, P. Baldassari, A. Guidetti, G. F. Gallino, M. Del Vecchio, F. Ravagnani, M. Magni, P. Chaplin, N. Cascinelli, G. Parmiani, A. M. Gianni and A. Anichini: Boosting T cellmediated immunity to tyrosinase by vaccinia virustransduced, CD34 (+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma. Clin Cancer Res, 10 (16), 5381-90 (2004). (Pubitemid 39100475)
126. J. B. Vermorken and V. F. Van Tendeloo: Dendritic cell therapy of cancer: can it fulfill its promise? Expert Rev Anticancer Ther, 3 (1), 1-3 (2003). (Pubitemid 36204433)
127. M. G. O'Rourke, M. K. Johnson, C. M. Lanagan, J. L. See, L. E. O'Connor, G. J. Slater, D. Thomas, J. A. Lopez, N. R. Martinez, K. A. Ellem and C. W. Schmidt: Dendritic cell immunotherapy for stage IV melanoma. Melanoma Res, 17 (5), 316-22 (2007). (Pubitemid 47462224)
128. M. Baudard, F. Comte, A. M. Conge, D. Mariano- Goulart, B. Klein and J. F. Rossi: Importance of (18F)fluorodeoxyglucose-positron emission tomography scanning for the monitoring of responses to immunotherapy in follicular lymphoma. Leuk Lymphoma, 48 (2), 381-8 (2007). (Pubitemid 46994889)
129. J. E. Wooldridge: Can a positive positron emission tomography scan be positive news? Leuk Lymphoma, 48 (2), 227-8 (2007).
130. T. Lesimple, E. M. Neidhard, V. Vignard, C. Lefeuvre, H. Adamski, N. Labarriere, A. Carsin, D. Monnier, B. Collet, G. Clapisson, B. Birebent, I. Philip, L. Toujas, M. Chokri and V. Quillien: Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intranodal routes in metastatic melanoma patients. Clin Cancer Res, 12 (24), 7380-8 (2006). (Pubitemid 46095412)
131. G. Reinhard, A. Marten, S. M. Kiske, F. Feil, T. Bieber and I. G. Schmidt-Wolf: Generation of dendritic cell-based vaccines for cancer therapy. Br J Cancer, 86 (10), 1529-33 (2002). (Pubitemid 34628103)
132. A. Matsumoto, K. Haraguchi, T. Takahashi, T. Azuma, Y. Kanda, K. Tomita, M. Kurokawa, S. Ogawa, K. Takahashi, S. Chiba and T. Kitamura: Immunotherapy against metastatic renal cell carcinoma with mature dendritic cells. Int J Urol, 14 (4), 277-83 (2007). (Pubitemid 46669054)
133. A. Tuettenberg, C. Becker, E. Huter, J. Knop, A. H. Enk and H. Jonuleit: Induction of strong and persistent MelanA/MART-1-specific immune responses by adjuvant dendritic cell-based vaccination of stage II melanoma patients. Int J Cancer, 118 (10), 2617-27 (2006).
134. Y. Waeckerle-Men, E. Uetz-von Allmen, M. Fopp, R. von Moos, C. Bohme, H. P. Schmid, D. Ackermann, T. Cerny, B. Ludewig, M. Groettrup and S. Gillessen: Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. Cancer Immunol Immunother, 55 (12), 1524-33 (2006). (Pubitemid 44327840)
135. A. K. Thomas-Kaskel, R. Zeiser, R. Jochim, C. Robbel, W. Schultze-Seemann, C. F. Waller and H. Veelken: Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival. Int J Cancer, 119 (10), 2428-34 (2006). (Pubitemid 44546968)
136. M. Salcedo, N. Bercovici, R. Taylor, P. Vereecken, S. Massicard, D. Duriau, F. Vernel-Pauillac, A. Boyer, V. Baron-Bodo, E. Mallard, J. Bartholeyns, B. Goxe, N. Latour, S. Leroy, D. Prigent, P. Martiat, F. Sales, M. Laporte, C. Bruyns, J. L. Romet-Lemonne, J. P. Abastado, F. Lehmann and T. Velu: Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate. Cancer Immunol Immunother, 55 (7), 819-29 (2006).
137. B. A. Tjoa, P. A. Lodge, M. L. Salgaller, A. L. Boynton and G. P. Murphy: Dendritic cell-based immunotherapy for prostate cancer. CA Cancer J Clin, 49 (2), 117-28, 65 (1999). (Pubitemid 29353925)
138. J. J. Patard: Dendritic cells for the treatment of metastatic renal cell carcinoma: at a low ebb? Eur Urol, 50 (1), 11-3 (2006).
139. D. Schadendorf, S. Ugurel, B. Schuler-Thurner, F. O. Nestle, A. Enk, E. B. Brocker, S. Grabbe, W. Rittgen, L. Edler, A. Sucker, C. Zimpfer-Rechner, T. Berger, J. Kamarashev, G. Burg, H. Jonuleit, A. Tuttenberg, J. C. Becker, P. Keikavoussi, E. Kampgen and G. Schuler: Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol, 17 (4), 563-70 (2006).
140. S. Danson and P. Lorigan: Melanoma vaccines-they should work. Ann Oncol, 17 (4), 539-41 (2006).
141. S. Fuessel, A. Meye, M. Schmitz, S. Zastrow, C. Linne, K. Richter, B. Lobel, O. W. Hakenberg, K. Hoelig, E. P. Rieber and M. P. Wirth: Vaccination of hormonerefractory prostate cancer patients with peptide cocktailloaded dendritic cells: results of a phase I clinical trial. Prostate, 66 (8), 811-21 (2006).
142. N. Okada, N. Mori, R. Koretomo, Y. Okada, T. Nakayama, O. Yoshie, H. Mizuguchi, T. Hayakawa, S. Nakagawa, T. Mayumi, T. Fujita and A. Yamamoto: Augmentation of the migratory ability of DC-based vaccine into regional lymph nodes by efficient CCR7 gene transduction. Gene Ther, 12 (2), 129-39 (2005). (Pubitemid 40185916)
143. M. D. Gunn, S. Kyuwa, C. Tam, T. Kakiuchi, A. Matsuzawa, L. T. Williams and H. Nakano: Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization. J Exp Med, 189 (3), 451-60 (1999). (Pubitemid 29187367)
144. R. Forster, A. Schubel, D. Breitfeld, E. Kremmer, I. Renner-Muller, E. Wolf and M. Lipp: CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell, 99 (1), 23-33 (1999). (Pubitemid 29468627)
145. A. K. Palucka, H. Ueno, J. Connolly, F. Kerneis- Norvell, J. P. Blanck, D. A. Johnston, J. Fay and J. Banchereau: Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J Immunother, 29 (5), 545-57 (2006). (Pubitemid 44395279)
146. E. J. Small, P. Fratesi, D. M. Reese, G. Strang, R. Laus, M. V. Peshwa and F. H. Valone: Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol, 18 (23), 3894-903 (2000).
147. A. Curti, P. Tosi, P. Comoli, C. Terragna, E. Ferri, C. Cellini, M. Massaia, A. D'Addio, V. Giudice, C. Di Bello, M. Cavo, R. Conte, G. Gugliotta, M. Baccarani and R. M. Lemoli: Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides. Br J Haematol, 139 (3), 415-24 (2007). (Pubitemid 47512192)
148. B. Kavanagh, A. Ko, A. Venook, K. Margolin, H. Zeh, M. Lotze, B. Schillinger, W. Liu, Y. Lu, P. Mitsky, M. Schilling, N. Bercovici, M. Loudovaris, R. Guillermo, S. M. Lee, J. Bender, B. Mills and L. Fong: Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. J Immunother (1997), 30 (7), 762-72 (2007). (Pubitemid 47480759)
149. D. E. Avigan, B. Vasir, D. J. George, W. K. Oh, M. B. Atkins, D. F. McDermott, P. W. Kantoff, R. A. Figlin, M. J. Vasconcelles, Y. Xu, D. Kufe and R. M. Bukowski: Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Immunother (1997), 30 (7), 749-61 (2007). (Pubitemid 47480758)
150. J. A. Kyte, L. Mu, S. Aamdal, G. Kvalheim, S. Dueland, M. Hauser, H. P. Gullestad, T. Ryder, K. Lislerud, H. Hammerstad and G. Gaudernack: Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumormRNA. Cancer Gene Ther, 13 (10), 905-18 (2006). (Pubitemid 44373791)
151. M. Katano, T. Morisaki, K. Koga, M. Nakamura, H. Onishi, K. Matsumoto, A. Tasaki, H. Nakashima and T. Akiyoshi: Combination therapy with tumor cell-pulsed dendritic cells and activated lymphocytes for patients with disseminated carcinomas. Anticancer Res, 25 (6A), 3771-6 (2005). (Pubitemid 41658451)
152. J. Babatz, C. Rollig, B. Lobel, G. Folprecht, M. Haack, H. Gunther, C. H. Kohne, G. Ehninger, M. Schmitz and M. Bornhauser: Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells. Cancer Immunol Immunother, 55 (3), 268-76 (2006). (Pubitemid 41682575)
153. R. Yamanaka, J. Homma, N. Yajima, N. Tsuchiya, M. Sano, T. Kobayashi, S. Yoshida, T. Abe, M. Narita, M. Takahashi and R. Tanaka: Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res, 11 (11), 4160-7 (2005). (Pubitemid 40791581)
154. H. A. Haenssle, S. W. Krause, S. Emmert, M. Zutt, L. Kretschmer, H. Schmidberger, R. Andreesen and A. Soruri: Hybrid cell vaccination in metastatic melanoma: clinical and immunologic results of a phase I/II study. J Immunother (1997), 27 (2), 147-55 (2004). (Pubitemid 38282734)
155. E. Ovali, T. Dikmen, M. Sonmez, M. Yilmaz, A. Unal, T. Dalbasti, K. Kuzeyli, M. Erturk and S. B. Omay: Active immunotherapy for cancer patients using tumor lysate pulsed dendritic cell vaccine: a safety study. J Exp Clin Cancer Res, 26 (2), 209-14 (2007). (Pubitemid 47025284)
156. I. Bleumer, D. M. Tiemessen, J. C. Oosterwijk- Wakka, M. C. Voller, K. De Weijer, P. F. Mulders and E. Oosterwijk: Preliminary analysis of patients with progressive renal cell carcinoma vaccinated with CA9- peptide-pulsed mature dendritic cells. J Immunother (1997), 30 (1), 116-22 (2007). (Pubitemid 46052210)
157. S. K. Burgdorf, A. Fischer, M. H. Claesson, A. F. Kirkin, K. N. Dzhandzhugazyan and J. Rosenberg: Vaccination with melanoma lysate-pulsed dendritic cells, of patients with advanced colorectal carcinoma: report from a phase I study. J Exp Clin Cancer Res, 25 (2), 201-6 (2006). (Pubitemid 44113864)
158. B. E. Loveland, A. Zhao, S. White, H. Gan, K. Hamilton, P. X. Xing, G. A. Pietersz, V. Apostolopoulos, H. Vaughan, V. Karanikas, P. Kyriakou, I. F. McKenzie and P. L. Mitchell: Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. Clin Cancer Res, 12 (3 Pt 1), 869-77 (2006). (Pubitemid 43259870)
159. J. W. Fay, A. K. Palucka, S. Paczesny, M. Dhodapkar, D. A. Johnston, S. Burkeholder, H. Ueno and J. Banchereau: Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptidepulsed CD34 (+) progenitor-derived dendritic cells. Cancer Immunol Immunother, 55 (10), 1209-18 (2006). (Pubitemid 43992047)
160. J. Banchereau, H. Ueno, M. Dhodapkar, J. Connolly, J. P. Finholt, E. Klechevsky, J. P. Blanck, D. A. Johnston, A. K. Palucka and J. Fay: Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptidepulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon. J Immunother (1997), 28 (5), 505-16 (2005). (Pubitemid 41232572)
161. L. M. Liau, R. M. Prins, S. M. Kiertscher, S. K. Odesa, T. J. Kremen, A. J. Giovannone, J. W. Lin, D. J. Chute, P. S. Mischel, T. F. Cloughesy and M. D. Roth: Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res, 11 (15), 5515-25 (2005). (Pubitemid 41060828)
162. K. H. Chi, S. J. Liu, C. P. Li, H. P. Kuo, Y. S. Wang, Y. Chao and S. L. Hsieh: Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma. J Immunother (1997), 28 (2), 129-35 (2005). (Pubitemid 40328199)
163. D. A. Caruso, L. M. Orme, G. M. Amor, A. M. Neale, F. J. Radcliff, P. Downie, M. L. Tang and D. M. Ashley: Results of a Phase I study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children with Stage 4 neuroblastoma. Cancer, 103 (6), 1280-91 (2005). (Pubitemid 40328101)
164. A. Ribas, J. A. Glaspy, Y. Lee, V. B. Dissette, E. Seja, H. T. Vu, N. S. Tchekmedyian, D. Oseguera, B. Comin- Anduix, J. A. Wargo, S. N. Amarnani, W. H. McBride, J. S. Economou and L. H. Butterfield: Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy. J Immunother (1997), 27 (5), 354-67 (2004). (Pubitemid 39121924)
165. D. A. Caruso, L. M. Orme, A. M. Neale, F. J. Radcliff, G. M. Amor, W. Maixner, P. Downie, T. E. Hassall, M. L. Tang and D. M. Ashley: Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer. Neuro Oncol, 6 (3), 236-46 (2004). (Pubitemid 39136507)
166. D. Avigan, B. Vasir, J. Gong, V. Borges, Z. Wu, L. Uhl, M. Atkins, J. Mier, D. McDermott, T. Smith, N. Giallambardo, C. Stone, K. Schadt, J. Dolgoff, J. C. Tetreault, M. Villarroel and D. Kufe: Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Res, 10 (14), 4699-708 (2004). (Pubitemid 38955520)
167. J. S. Yu, G. Liu, H. Ying, W. H. Yong, K. L. Black and C. J. Wheeler: Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res, 64 (14), 4973- 9 (2004). (Pubitemid 38924545)
168. I. M. Svane, A. E. Pedersen, H. E. Johnsen, D. Nielsen, C. Kamby, E. Gaarsdal, K. Nikolajsen, S. Buus and M. H. Claesson: Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. Cancer Immunol Immunother, 53 (7), 633-41 (2004). (Pubitemid 38858337)